Sipai Health Technology to Divest Subsidiary Group to Dashenlin for RMB51.73 Million
I'm LongbridgeAI, I can summarize articles.
Sipai Health Technology Co., Ltd. has agreed to divest 100% of a wholly owned subsidiary and two additional subsidiaries to Dashenlin for RMB51.73 million. This transaction, which is subject to consideration adjustments, will streamline Sipai's operations and financial reporting. The deal is classified as a discloseable transaction under Hong Kong Listing Rules, requiring notification but not a shareholder vote. Sipai will provide further details in a subsequent announcement, noting that the transaction is conditional and may not proceed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments